Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
See Attems and Jellinger (doi:10.1093/brain/awx360) for a scientific commentary on this article.Cognitive changes occurring throughout the pathogenesis of neurodegenerative diseases are directly linked to synaptic loss. We used in-depth proteomics to compare 32 post-mortem human brains in the prefrontal cortex of prospectively followed patients with Alzheimer's disease, Parkinson's disease with dementia, dementia with Lewy bodies and older adults without dementia. In total, we identified 10 325 proteins, 851 of which were synaptic proteins. Levels of 25 synaptic proteins were significantly altered in the various dementia groups. Significant loss of SNAP47, GAP43, SYBU (syntabulin), LRFN2, SV2C, SYT2 (synaptotagmin 2), GRIA3 and GRIA4 were further validated on a larger cohort comprised of 92 brain samples using ELISA or western blot. Cognitive impairment before death and rate of cognitive decline significantly correlated with loss of SNAP47, SYBU, LRFN2, SV2C and GRIA3 proteins. Besides differentiating Parkinson's disease dementia, dementia with Lewy bodies, and Alzheimer's disease from controls with high sensitivity and specificity, synaptic proteins also reliably discriminated Parkinson's disease dementia from Alzheimer's disease patients. Our results suggest that these particular synaptic proteins have an important predictive and discriminative molecular fingerprint in neurodegenerative diseases and could be a potential target for early disease intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In both conditions, these altered functions largely originate from synaptic dysfunction relating to altered synaptic proteomes31,32.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies of postmortem human brains have found the significant association between cognitive decline and the loss of synaptic proteins in PFC, such as SNAP25, SNAP47, SV2C, SYT2 and GRIA3 253,254”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [253]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Synapses are the hub of neuron communications, and their degeneration is widely observed across multiple neurodegenerative diseases and increasingly recognized as a central cause of dementia 2,4,5,8,16 .”
From NAD+ hydrolase Sarm1 is a key driver of synapse degeneration and memory loss in Alzheimer’s disease (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“suggesting that these PFC synaptic markers are predictive molecular fingerprint for neurodegenerative diseases”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [253]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“Cognitive data were available for most patients and consisted of the last Mini-Mental State Examination (MMSE) scores, assessed in most cases within 1–2 years before death (Folstein et al., 1975) and MMSE decline calculated as average decline over a period of clinical observation of 8–10 years.”
MethodSystematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
Universal sample preparation method for proteome analysis
Wiśniewski, J. R., Zougman, A., Nagaraj, N., & Mann, M. (2009) · Nature Methods · doi:10.1038/nmeth.1322 · Cited by 8,352
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 2×
“, 2010), a characteristic feature in Alzheimer’s disease (Terry et al., 1991; Honer, 2003) and increasing attention is now being devoted to their role in synucleinopathies (Aarsland et al.”
BackgroundThe molecular biology of memory storage: a dialogue between genes and synapses
Kandel, E. R. (2001) · Science · doi:10.1126/science.1067020 · Cited by 3,917
Cited by
Items 101–200 of 222
Human Cerebral Cortex Proteome of Fragile X-Associated Tremor/Ataxia Syndrome
Holm, K. N., Herren, A. W., Taylor, S. L., Randol, J. L., Kim, K., Espinal, G. M., Martínez‐Cerdeño, V., Pessah, I. N., Hagerman, R. J., & Hagerman, P. J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.600840 · Cited by 19
“While Ca2+ dysregulation is a common hallmark of neurodegenerative diseases, Ca2+associated proteins commonly present with increased abundance in neurodegenerative diseases (Hondius et al., 2016; Bereczki et al., 2018).”
BackgroundFrom protein biomarkers to proteomics in dementia with Lewy Bodies
Tsamourgelis, A., Swann, P., Chouliaras, L., & O'Brien, J. T. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101771 · Cited by 19
Chen, J., Zhang, Y., Liu, X., Li, K., Liu, H., Lai, W., Shi, Y., Xi, Z., Yan, L., Tian, L., et al. (2023) · Environmental Pollutants and Bioavailability · doi:10.1080/26395940.2023.2292104 · Cited by 17
“Cognitive impairment and decline in rats have been linked to reduced SYBU expression, suggesting its significant predictive value in dementia diseases such as Alzheimer’s [38].”
Proteomic signatures of Alzheimer's disease and Lewy body dementias: A comparative analysis
Canal-García, A., Branca, R. M., Francis, P. T., Ballard, C. G., Winblad, B. G., Lehtiö, J., Nilsson, P., Aarsland, D., Pereira, J. B., & Bereczki, E. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14375 · Cited by 23
Self-citationGao, Z., Zhang, R., Jiang, L., Zhou, H., Wang, Q., Ma, Y., Zhang, D., Qin, Y., Tian, P., Zhang, N., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215301 · Cited by 18
“Studies have found that the length of the synaptic active area and the thickness of PSD in AD model mice are reduced [48].”
Bencze, J., Szarka, M., Bencs, V., Szabó, R. N., Smajda, M., Aarsland, D., & Hortobágyi, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-53638-9 · Cited by 17
Self-citationA Meta-Analysis on Presynaptic Changes in Alzheimer’s Disease
Anschuetz, A., Schwab, K., Harrington, C. R., Wischik, C. M., & Riedel, G. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-231034 · Cited by 14
Pramanik, S., Harini Devi, M., Chakrabarty, S., Paylar, B., Pradhan, A., Thaker, M., Ayyadhury, S., Manavalan, A., Olsson, P., Pramanik, G., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105834 · Cited by 20
Mohanraj, N., Joshi, N. S., Poulose, R., Patil, R. R., Santhoshkumar, R., Kumar, A., Waghmare, G., Saha, A. K., Haider, S. Z., Markandeya, Y. S., et al. (2022) · Toxicology Reports · doi:10.1016/j.toxrep.2022.07.002 · Cited by 14
Ke, P., Gu, J., Liu, J., Liu, Y., Tian, X., Ma, Y., Meng, Y., & Xiao, F. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01461-7 · Cited by 18
“In proteomic analysis of postmortem cortices from patients with Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease, syntabulin expression changes significantly [17].”
BackgroundBrains for Dementia Research: The Importance of Cohorts in Brain Banking
Francis, P. T., Hayes, G. M., Costello, H., & Whitfield, D. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-018-0327-2 · Cited by 16
Self-citationVe, H., Cabana, V. C., Gouspillou, G., & Lussier, M. P. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.06.044 · Cited by 16
Ghali, M. G. Z., Marchenko, V., Yasargil, M. G., & Ghali, G. Z. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105022 · Cited by 15
Uncovering Discrete Synaptic Proteomes to Understand Neurological Disorders
Wang, Y., & Savas, J. N. (2018) · Proteomes · doi:10.3390/proteomes6030030 · Cited by 12
“Specific brain regions, neurons, synapses, and synaptic proteins are also impaired in Alzheimer’s disease (AD) [12,13].”
BackgroundVidyadhara, D. J., Bäckström, D. C., Chakraborty, R., Ruan, J., Park, J.-M., Mistry, P. K., & Chandra, S. S. (2025) · Nature Communications · doi:10.1038/s41467-025-63444-9 · Cited by 17
Wei, W., Jiang, Y. Y., Hu, G., He, Y., & Chen, H. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240092 · Cited by 14
“193 Overall, mitochondrial trafficking failure in the context of AD is mediated by disordered energy, MMP destabilization and dysfunctional transport machinery caused by the interference of several motor, cytoskeleton and adaptor protein functions.”
Loke, Y. J., Muggli, E., Saffery, R., Ryan, J. L., Lewis, S., Elliott, E. J., Halliday, J. L., & Craig, J. M. (2021) · Epigenomics · doi:10.2217/epi-2021-0285 · Cited by 17
Kumar, A., Doan, V. M., Kunkli, B., & Csősz, É. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.633050 · Cited by 14
Zhang, Y., Hu, Y., Han, Z., Geng, Y., Xia, Z., Zhou, Y., Wang, Z., Wang, Y., Kong, E., Wang, X., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220009 · Cited by 12
Levitsky, L. I., Ivanov, M. V., Goncharov, A. O., Kliuchnikova, A. A., Bubis, J. A., Lobas, A. A., Solovyeva, E. M., Pyatnitskiy, M. A., Ovchinnikov, R. K., Kukharsky, M. S., et al. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00740 · Cited by 11
Using Proteomics to Understand Alzheimer’s Disease Pathogenesis
Drummond, E., & Wısnıewskı, T. (2019) · Codon Publications eBooks · doi:10.15586/alzheimersdisease.2019.ch3 · Cited by 19
“Other studies have used their bulk tissue homogenate results to look specifically at synaptic protein changes (34, 68); however, these results could potentially miss differences in low abundance synaptic proteins.”
ResultKumar, N., Singh, V. P., Li, L., Willard, B. B., Tripathi, A. K., & Dutta, R. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.779003 · Cited by 15
Saunders, T. S., Gadd, D. A., Spires‐Jones, T. L., King, D., Ritchie, C. W., & Terrera, G. M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15656 · Cited by 13
Zhang, T., Musheshe, N., van der Veen, C. H. T. J., Kessels, H. W. H. G., Dolga, A. M., Deyn, P. P. D., Eisel, U. L. M., & Schmidt, M. (2023) · Biomedicines · doi:10.3390/biomedicines11082096 · Cited by 12
“Interestingly, it has been reported that protein expression of GluA3 decreased in hippocampal synaptosomes of AD patients [47] and increased in CSF of AD patients [40].”
BackgroundReus, L. M., Stringer, S., Posthuma, D., Teunissen, C. E., Scheltens, P., Pijnenburg, Y. A. L., Visser, P. J., & Tijms, B. M. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.012 · Cited by 12
“Synaptic loss has been observed in a variety of neurodegenerative disorders and is directly linked to cognitive decline (Bereczki et al., 2018).”
Xu, J., Li, J., Sun, Y.-J., Quan, W., Liu, L., Zhang, Q., Qin, Y., Pei, X., Su, H., & Chen, J. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1029370 · Cited by 15
“Synaptic proteins reliably discriminated PDD and DLB from controls with high sensitivity and specificity (39).”
BackgroundElucidating distinct molecular signatures of Lewy body dementias
Harvey, J., Pishva, E., Chouliaras, L., & Lunnon, K. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106337 · Cited by 12
“In their more recent study they identified and assayed expression of 10,325 proteins in AD, DLB and PDD prefrontal cortex (Bereczki et al., 2018).”
BackgroundImpact of unilateral ureteral obstruction on cognition and neurodegeneration
Ho, J. Y. S., Lau, C. G., Lee, K., Tan, J.-Y., Lee, J., Yung, S., & Chang, R. C. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.01.001 · Cited by 12
Shwab, E. K., Pathak, G. A., Harvey, J., Belloy, M. E., Fischer, C. E., Lutz, M. W., Scholz, S. W., Cook, N., Reid, D. M., Chen, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70549 · Cited by 17
Ormiston, K., Melink, Z., Andridge, R., Lustberg, M. B., DeVries, A. C., Murphy, K., Emmers, K., Ziouzenkova, O., Belury, M. A., & Orchard, T. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.09.021 · Cited by 10
Wagner, L. M., Nathwani, S. M., Eyck, P. P. T., & Aldridge, G. M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135051 · Cited by 10
“Loss of synapses and synaptic proteins may precede cell loss in Alzheimer’s disease and other dementias and correlates with the severity of cognitive dysfunction [5, 24, 28].”
BackgroundYi, X., Li, J.-Y., Tang, Z., Jiang, S., Liu, Y., Deng, J., & Gao, C. (2020) · Pharmaceutical Biology · doi:10.1080/13880209.2020.1837187 · Cited by 11
“A recent study (Bereczki et al. 2018) used in-depth proteomics to compare 32 post-mortem human brains in the prefrontal cortex of prospective AD patients, PD patients with dementia, dementia patients with Lewy bodies, and older adults without dementia.”
BackgroundFisher, D. W., Tulloch, J., Yu, C., & Tsuang, D. W. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr220114 · Cited by 11
Shen, Y., Ali, M., Timsina, J., Wang, C., Do, A. N., Western, D., Liu, M., Gorijala, P., Budde, J., Liu, H., et al. (2024) · medRxiv · doi:10.1101/2024.01.12.24301242 · Cited by 11
Reinders, N. R., van der Spek, S. J. F., Klaassen, R. V., Koymans, K. J., MacGillavry, H. D., Smit, A. B., & Kessels, H. W. H. G. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.0393-24.2024 · Cited by 9
“…with cognitive decline in mild cognitively impaired individuals and AD patients (Armstrong et al., 1994; Yasuda et al., 1995; Armstrong and Ikonomovic, 1996; Carter et al., 2004; Bodily et al., 2016; Hondius et al., 2016; Bereczki et al., 2018; Enache et al., 2020; Medina-Vera et al., 2023).”
Mantash, S., Aboulouard, S., Dakik, H., Zirem, Y., Ziane-Chaouche, L., Nehme, A., Mallah, K., El-Kurdi, M., Ramadan, N., Fournier, I., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02286-9 · Cited by 14
“72,73 In a proteomic approach performed on postmortem human brains with AD and Parkinson ’ s disease with dementia (PDD), and dementia with Lewy bodies (DLB), a signi fi cant correlation was found between cognitive impairment and loss of Gria3 protein before death.”
Identification of the changes in the platelet proteomic profile of elderly individuals
Chen, H.-L., Wang, Q.-Y., Qi, R., & Cai, J.-P. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1384679 · Cited by 11
Bencs, V., Bencze, J., Módis, V. L., Simon, V., Kálmán, J., & Hortobágyi, T. (2020) · Orvosi Hetilap · doi:10.1556/650.2020.31715 · Cited by 9
Self-citationA Panel of Synapse-Related Genes as a Biomarker for Gliomas
Ji, X., Zhang, H., & Cui, Q. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00822 · Cited by 12
Godfrey, R. K., Alsop, E. B., Bjork, R. T., Chauhan, B. S., Ruvalcaba, H. C., Antone, J., Gittings, L. M., Michael, A. F., Williams, C., Hala’ufia, G., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01656-0 · Cited by 15
Enduru, N., Fernandes, B. S., & Zhao, Z. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1376050 · Cited by 9
Proteomics for synaptic markers of cognitive decline in neurodegenerative diseases
Attems, J., & Jellinger, K. A. (2017) · Brain · doi:10.1093/brain/awx360 · Cited by 8
Gaudreault, R., Hervé, V., van de Ven, T. G. M., Mousseau, N., & Ramassamy, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201549 · Cited by 10
“These altered functions largely originate from 10 synaptic dysfunction involving altered synaptic proteomes [35, 36] with the particular contribution of 11”
Zhu, L., Fan, J., Chao, F., Zhou, C., Jiang, L. H., Zhang, Y., Luo, Y., Zhang, L., Xiao, Q., Yang, H., et al. (2021) · The Journal of Comparative Neurology · doi:10.1002/cne.25252 · Cited by 8
“Bereczki et al. (2018) showed that decreased levels of synaptic proteins in the PFC correlate with cognitive decline.”
BackgroundSartori, B. M., Júnior, R. E. M., Paiva, I. M., Moraes, I. B., Murgas, L. D. S., & Godard, A. L. B. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114352 · Cited by 8
Liu, M., Zhu, L., Guo, Y., Zhang, S., Jiang, L. H., Zhang, Y., Chao, F., & Tang, Y. C. (2023) · The Journal of Comparative Neurology · doi:10.1002/cne.25485 · Cited by 8
“It has been shown that in AD patients with a reduced number of dendritic spines, decreases in the intracortical synaptic density andexpressionof synapse-associated proteins may be associated with cognitive decline (Bereczki et al., 2018; Boros et al., 2017; Poirel et al., 2018).”
BackgroundZhao, F., Bordoni, L., Min, W., & Gabbianelli, R. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c01755 · Cited by 8
Synaptic organizers: synaptic adhesion-like molecules (SALMs)
Liu, H. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.01.002 · Cited by 10
Bencze, J., Szarka, M., Bencs, V., Szabó, R. N., Módis, L., Aarsland, D., & Hortobágyi, T. (2020) · Brain Sciences · doi:10.3390/brainsci10020068 · Cited by 10
Self-citationProteomic Characterization of the Olfactory Molecular Imbalance in Dementia with Lewy Bodies
Lachén‐Montes, M., Mendizuri, N., Schvartz, D., Fernández‐Irigoyen, J., Sánchez, J. C., & Santamaría, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176371 · Cited by 8
“In addition, among those synapsis-related deregulated proteins, Rab3b significantly downregulated in the OB of DLB subjects has been recently proposed as a predictive marker for cognitive decline in DLB patients [33].”
BackgroundResultInfluentialFluid markers of synapse degeneration in synucleinopathies
Cervantes González, A., & Belbin, O. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02467-8 · Cited by 7
Zou, Y., Guo, Q., Chang, Y., Zhong, Y., Cheng, L. Z., & Wei, W. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110518 · Cited by 7
Liu, F., Bao, Y., Qiu, B., Mao, J., Liao, X., Huang, H., Zhang, A., Zhang, G., Qi, S., & Mei, F. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.861425 · Cited by 7
“CSF biomarkers have been proven useful in several disorders, such as depressive disorder and Alzheimer’s disease (AD; Bereczki et al., 2018; Al Shweiki et al., 2020).”
BackgroundCastillo-Morales, A., Monzón‐Sandoval, J., Urrutia, A. O., & Gutiérrez, H. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.015 · Cited by 6
Rho‐kinase inhibition by fasudil modulates pre‐synaptic vesicle dynamics
Saal, K. A., Arias, C. C. W. P., Roser, A., Koch, J. C., Bähr, M., Rizzoli, S. O., & Lingor, P. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15274 · Cited by 6
Long Noncoding RNA SNHG7 Is a Diagnostic and Prognostic Marker for Colon Adenocarcinoma
Jiang, C., Qu, S., Liu, T., & Hao, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.893591 · Cited by 7
Restoring synaptic function through multimodal therapeutics
Loera‐Valencia, R., Ismail, M.-A.-M., Nilsson, P., & Winblad, B. G. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.003 · Cited by 6
Self-citationSoto-Ospina, A., Marín, P. A., Bedoya, G., Falla, D. S., & Lanau, A. V. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.649990 · Cited by 9
“Neurodegenerative diseases are characterized by impairment of the central nervous system (Bereczki et al., 2018).”
BackgroundRecent advances in genetics of aggressive behavior
Davydova, Y. D., Litvinov, S., Enikeeva, R. F., Malykh, S. B., & Хуснутдинова, Э. К. (2018) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vj18.415 · Cited by 10
Vera, D. M., Enache, D., Tambaro, S., Abuhashish, E., Rosell‐Valle, C., Winblad, B. G., de Fonseca, F. R., Bereczki, E., & Nilsson, P. (2022) · Brain Communications · doi:10.1093/braincomms/fcad001 · Cited by 5
“ing along with the robust decrease in neurogranin, PSD95 or GluA3 levels region dependent changes in ZnT3 and Dyn1 levels.(19,21,44)”
BackgroundSelf-citationJia, T., Yang, F., Qin, F., He, Y., Han, F., & Zhang, C. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70370 · Cited by 9
“Moreover, substantial transcriptional and translational alterations in PD and LBD patients have been demonstrated in this brain region [16–18].”
DL-3-n-butylphthalide enhances synaptic plasticity in mouse model of brain impairments
Ding, Q., Yu, Q., Lei, T., Guo, Y., Zhao, J., & Yu, J. J. (2022) · STEMedicine · doi:10.37175/stemedicine.v3i1.113 · Cited by 5
Human Brain Banking as a Convergence Platform of Neuroscience and Neuropsychiatric Research
Liu, F., Yin, X., Cong, C., Wang, Y., & Ma, C. (2022) · Human Brain · doi:10.37819/hb.001.001.0204 · Cited by 5
Niu, R., Feng, W.-Q., Chen, L., & Bao, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104841 · Cited by 6
“The AMPA receptor subunit GRIA4 [102,103] and microtubule regulator STMN2 [104,105] completed this network of dysfunction, together painting a picture of compromised excitatory transmission and impaired neuronal maintenance.”
Li, X., Wan, R., Zhao, Y., Wu, Y., Chen, X., Li, Q., & Luo, C. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103028 · Cited by 7
Systematic review of differentially abundant proteins in people with Lewy body dementia
Farr, L. M., Thorpe, N., Brinda, E. M., Al‐Balushi, N., Sohail, M., & Rajkumar, A. P. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.15 · Cited by 5
Association between neurodegenerative diseases and pneumonia: a retrospective population-based study
Yeh, J., Lin, C., Hsu, C. Y., Shae, Z., & Kao, C. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1552408 · Cited by 4
“In addition, the guidelines on Using Refill Slip for Chronic Illness Prescription include: (1) to avoid running out of medicine, patients should be sure to take their prescription to the clinic or hospital where they were originally diagnosed or a NHI-contracted pharmacy within 10 days of when the medication will run…”
ResultHassan, Z., & Sriramaneni, R. N. (2021) · Neuroscience Research Notes · doi:10.31117/neuroscirn.v4i3.77 · Cited by 4
Li, X., Xu, X., Zhang, J., Wang, X., Zhao, C., Liu, Q., & Fan, K. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118588 · Cited by 5
Korukonda, A., Blankenship, H. E., Kam, K., Kour, D., Espinosa‐García, C., Jang, W. E., Srivastava, U., Mulvey, B., Tish, M. M., Witztum, R., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03852-5 · Cited by 6
Heo, C., Kwak, H.-J., Hoang, L. N., Woo, R., & Lee, S.-J. (2023) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2023.110029 · Cited by 4
“Subsequently, the expression of the Gria4 , Grin1 , and Nlrp3 genes (Bereczki et al., 2018; Wang et al., 2021; Liang et al., 2022) and the Cntnap1, Cxcl11 , and Mmp9 genes (Tang et al., 2020; Wojcieszak et al., 2022; Panda et al., 2022; Ringland et al., 2021; Gu et al., 2020) in the monomer A β 42…”
Xiong, L., Li, Q., Zhou, X., Xiao, J., Yang, X., Xu, H., & Guo, C. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823241312970 · Cited by 4
“35,36 An estimated 15% of patients with aMCI progress to AD each year.”
Dementia with Lewy bodies – a clinicopathological update
Bencze, J., Seo, W., Hye, A., Aarsland, D., & Hortobágyi, T. (2019) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-2613 · Cited by 4
Self-citationShalaby, A. M., Soliman, N., Elshamy, A. M., Alnasser, S. M., Alorini, M., Alsaykhan, H., Jaber, F. A., Alabiad, M. A., Younes, A. M., Elshaer, M. M. A., et al. (2025) · Microscopy and Microanalysis · doi:10.1093/mam/ozaf062 · Cited by 2
Espinosa‐García, C., Srivastava, U., Kumar, P., Kour, D., Malepati, S., Tobin, B. R., Xiao, H., Sunna, S. N., Bowen, C. A., Cheng, L., et al. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00024-1 · Cited by 3
“Consistently in AD, Snap47 levels decreased, among other synaptic proteins, correlating with the severity of cognitive decline [24, 67, 105].”
Glebov, O. O., Williamson, D. J., Owen, D. M., Hortobágyi, T., Troakes, C., & Aarsland, D. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12852 · Cited by 1
Self-citationProteome points to synaptic dysfunction in dementia
Ridler, C. E. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.5 · Cited by 2
Proteomics As A Valid Tool In Biomarker Discovery For Alzheimer's DiseasePreprint
Magnelli, V. (2024) · Preprints.org · doi:10.20944/preprints202401.1595.v1 · Cited by 1
Vidyadhara, D. J., Bäckström, D. C., Chakraborty, R., Ruan, J., Park, J. M., Mistry, P. K., & Chandra, S. S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.23.619548 · Cited by 2
Jawaid, T. (2024) · International Journal of Pharmacology · doi:10.3923/ijp.2024.22.33 · Cited by 1
Li, T., & Guo, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0316179 · Cited by 3
Pad2 deletion induces anxiety‑like behaviors and memory deficits in mice
Lv, X., Deng, H., Li, C., Gao, W., Zhang, Y., Gao, Y., Zhao, B., Shi, C., Gao, J., & Liu, Z. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111327 · Cited by 1
“- p More recently , SV2C are increasingly implicated in diseases such as Alzheimer’s disease and Parkinson’s disease[54]. e Extensive SV2C loss in the brains of PD patients compared to controls has been reported[55].”
Stone, T. W., Clanchy, F. I. L., & Williams, R. O. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1885761 · Cited by 1
Juan, D., García-Pérez, R., Esteller-Cucala, P., Martín, G. M., Lobón, I., Carlo, V. D., Riera, M., Kuhlwilm, M., Navarro, A., Blancher, A., et al. (2020) · DIGITAL.CSIC (Spanish National Research Council (CSIC)) · Cited by 1
Dendritic spines are lost in clusters in Alzheimer’s diseasePreprint
Mijalkov, M., Volpe, G., Fernaud-Espinosa, I., DeFelipe, J., Pereira, J. B., & Merino‐Serrais, P. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.20.346718 · Cited by 1
“With increasing recognition of AD as a synaptic disorder [33], maintaining the function of spines may become an important therapeutic target in the future.”
BackgroundSelf-citationHalbgebauer, S., Fazeli, B., Klose, V., Nagel, G., Rosenbohm, A., Rothenbacher, D., Bachhuber, F., Jesse, S., Otto, M., Landwehrmeyer, G. B., et al. (2024) · medRxiv · doi:10.1101/2024.12.04.24318285 · Cited by 1
NAD+ hydrolase Sarm1 is a key driver of synapse degeneration and memory loss in Alzheimer’s disease
Fan, F., Joshi, P., Liu, X., Kotturu, S. K., Abiola, M., Liu, Q., & Lou, X. (2025) · doi:10.64898/2025.12.21.695860
Identifying stage-specific markers of Alzheimer's disease using quantitative proteomics
Yagensky, O. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7052
Deciphering cell-type specific signal transduction in the brain: Challenges and promises
Roussarie, J.-P., & Rodriguez‐Rodriguez, P. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.09.009
P.288 CSF synaptic proteins and depressive symptoms in the elderly with and without dementia
Enache, D., Ptacek, S. G., Pereira, J. B., Winblad, B. G., Nilsson, P., Aarsland, D., & Bereczki, E. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.09.215
Self-citationNeuroproteomics: How a Multitude of Proteins Reflect Brain Functions
Гомазков, О. А. (2021) · Biology Bulletin Reviews · doi:10.1134/s2079086421020043 · Cited by 1
β-amyloid−driven synaptic depression requires PDZ protein interaction at AMPA-receptor subunit GluA3Preprint
Reinders, N. R., van der Spek, S. J. F., Klaassen, R. V., Koymans, K. J., Li, K. W., Smit, A. B., & Kessels, H. W. H. G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.03.462970
“Furthermore, GluA3 has been implicated to be associated with AD (Carter et al., 2004, Bodily et al., 2016, Boyle et al., 2006, Thorns et al., 1997, Bereczki et al., 2018).”
BackgroundMedia violance and how it`s impact on audience
Nazarova, I. V. (2021) · Век информации (сетевое издание) · doi:10.33941/age-info.com54(17)1
“Apart from that, functioning disorders in the LRFN2 gene product involved in cellular adhesion and plasticity, as well as in excitatory synapse development, are traditionally attributed to a series of cognitive disorders (Bereczki et al., 2018).”
BackgroundJiang, T., Li, Y., He, S., Du, M., Zhai, Q., Pu, K., Wu, M., Yan, C., Ma, Z., & Wang, Q. (2022) · Research Square · doi:10.21203/rs.3.rs-1446406/v1
Ashford, J. W. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734280398.793553881
Dendritic spine plasticity and traumatic brain injury
Xiong, Y., Mahmood, A., & Chopp, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823036-7.00036-0 · Cited by 1
Hegde, A., Upadhyay, S. S., Prasad, T. S. K., & Modi, P. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19084-1.00007-7 · Cited by 2
Proteomic-Based Studies on Memory Formation in Normal and Neurodegenerative Disease-Affected Brains
Beraldo, I. J. S., Rodrigues, M. P., Polanczyk, R. S., Verano‐Braga, T., & Lopes‐Aguiar, C. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-50624-6_7
Schueller, E., Grgurina, I., Cosquer, B., Panzer, É., Penaud, N., de Vasconcelos, A. P., Stéphan, A., Mérienne, K., Cassel, J., Mathis, C., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106676
“Several lines of evidence have verified a pronounced correlation between the decrease in synaptic markers with the onset of cognitive deficits (Bereczki et al., 2016; Bereczki et al., 2018).”
Metadata
- Authors
- Bereczki, E., Branca, R. M., Francis, P. T., Pereira, J. B., Baek, J.-H., Hortobágyi, T., Winblad, B., Ballard, C., Lehtiö, J., & Aarsland, D.
- Affiliations
- Karolinska Institutet (SE)
- Science for Life Laboratory (SE)
- King's College London (GB)
- University of Debrecen (HU)
- Corresponding author
- Bereczki, Erika
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01-09
- Volume
- 141
- Issue
- 2
- Pages
- 582-595
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC5837272
- OpenAlex
- W2782564735
- Cited by
- 220
- References
- 71
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 31 · 2023: 25 · 2022: 29 · 2021: 32 · 2020: 36 · 2019: 21 · 2018: 17
- FWCI
- 17.06
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- Alzheimerfonden
- Parkinsonfonden
- Stohnes Stiftelse
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- synaptic proteins, cognitive decline, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, prefrontal cortex, SV2C, GRIA3, synaptotagmin 2, protein biomarkers, differential diagnosis
- MeSH terms
- Aged, Aged, 80 and over, Brain, Cognition Disorders, Female, Gene Expression Regulation, Humans, Male, Membrane Proteins, Microtubule-Associated Proteins, Nerve Tissue Proteins, Neurologic Examination, Neuropsychological Tests, Synapses, Neurodegenerative Diseases, Proteomics, Intracellular Signaling Peptides and Proteins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.